OHSS Yönetimi

Stouffs K, Daelemans S, Santos-Ribeiro S, et al. Rare genetic variants potentially involved in ovarian hyperstimulation syndrome. J Assist Reprod Gene 2019;36(3):491-497.

Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 2014;101: 967–973.

Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85:112–120

Sahin Y, Kontaş O, Cankurtaran M. Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit. Gynecol Endocrinol. 1997;11(4):231-236.

McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-236.

Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 2000;74:429–438

Soares SR, Gomez R, Simon C, et al. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008;14:321-333

Golan A, Weissman A. Symposium: update on prediction and management of OHSS. A modern classification of OHSS. Reprod Biomed Online. 2009;19:28–32

Practice Committee of the American Society for Reproductive MedicinePrevention of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2024;121:230-245

Royal College of Obstetricians and Gynaecologists. The management of Ovarian Hyperstimulation Syndrome: Green-Top Guideline No. 5. 3rd ed. London: RCOG 2016.

Griesinger G, Verweij PJ, Gates D, et al. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol. PloS one 2016;11: (3):1-14

Papanikolaou EG, Humaidan P, Polyzos NP, et al. Identification of the high-risk patient for ovarian hyperstimulation syndrome. Semin Reprod Med 2010, 28:458–462.

Schouten N, Wang R, Torrance H, et al. Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis. Hum Reprod Update 2025;31(2):116-132.

Nakhuda GS, Chu MC, Wang JG, et al. Elevated serum Mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 2006;85:1541–1543.

Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antiMullerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol 2014;211(1):59.e1-8.

Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. J Fertil Steril 2012;98(3):657-663.

Sousa M, Cunha M, Teixeira da Silva J, et al. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles. Reprod Biol Endocrinol 2015;13:66. DOI 10.1186/s12958-015-0067-3

Selter J, Wen T, Palmerola KL, et al. Life– threatening complications among women with severe ovarian hyperstimulation syndrome. Am J Obstet Gynecol 2019;220(6):575.e1-575.e11.

Nenonen HA, Lindgren IA, Prahl AS, et al. The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation. Pharmacogenet Genomics 2019;29:114–120.

Tso LO, Costello MF, Albuquerque LET, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2020;12: Cd006105

Hussein RS, Elnashar I, Amin AF, et al. Effect of Metformin on Premature Luteinization and Pregnancy Outcomes in Intracytoplasmic Sperm Injection-Fresh Embryo Transfer Cycles: A Randomized Double-Blind Controlled Trial. Int J Fertil Steril 2021;15: 108-114.

Toftager M, Bogstad J, Bryndorf T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod 2016;31:1253–1264.

Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016;4:CD001750.

Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev 2017;1(1):CD012103.

Lambalk CB, Banga FR, Huirne JA, et al.. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update 2017;23:560–579.

Wang R, Lin S, Wang Y, et al. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: a systematic review and meta-analysis. PLoS ONE 2017;12:e0175985.

Kadoura S, Alhalabi M, Nattouf AH. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis. Sci Rep 2022;12:4456.

Palomba S, Costanzi F, Nelson SM, et al. Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence. Reprod Biol Endocrinol 2023;21(1):67.

Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod 2018;33:229–237.

Massin N. New Stimulation Regimens: Endogenous and Exogenous Progesterone Use to Block the LH Surge During Ovarian Stimulation for IVF. Hum Reprod Update 2017;23:211–220.

Ye H, Shi L, Quan X, et al. Cumulative live birth rate of in vitro fertilization cycle via progestin-primed ovarian stimulation versus gonadotropin-releasing hormone antagonist protocol in infertile women with normal ovarian reserve: an open-label, randomized controlled trial. Human fertility 2024;27, No1, 1-10. 2316005.

Guan S, Feng Y, Huang Y, et al. Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: a meta- analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2021;12:702558.

Chen ZQ, Ai A, Zhang Y, et al. A randomized controlled trial to compare the live birth rate of the first frozen embryo transfer following the progestin-primed ovarian stimulation protocol vs. the antagonist protocol in women with an anticipated high ovarian response. Fertil steril 2024;121: 937-945.

Iaconelli CAR, Setti AS, Braga DPAF, et al. Concomitant use of FSH and low-dose recombinant hCG during the late follicular phase versus conventional controlled ovarian stimulation for intracytoplasmic sperm injection cycles. Hum Fertil (Camb) 2017;20:285–292.

Lensen SF, Wilkinson J, Leijdekkers JA, et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev 2018;2:CD012693.

Oudshoorn SC, van Tilborg TC, Eijkemans MJC, et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder. Hum reprod 2017;32: 2506-2514.

Schouten N, Wang R, Torrance H, et al. Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis. Hum Reprod Update 2025;31(2):116-132.

Ngwenya O, Lensen SF, Vail A,et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev 2024;1: Cd012693.

Kamath MS, Maheshwari A, Bhattacharya S, et al. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. Cochrane Database Syst Rev 2017;11:CD008528

Sohrabvand F, Sheikhhassani S, Bagheri M et al. Comparison of highly purified urinary versus recombinant FSH: Effect on ART outcomes in polycystic ovary syndrome. Iran J Reprod Med 2012;10(3):229-236.

Van Wely M, Kwan I, Burt AL, et al. HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev 2011;2011:CD005354.

Cozzolino M, Vitagliano A, Cecchino GN, et al. Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2019;111:722–733.

D'Angelo A, Brown J, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011 Jun 15;(6):CD002811.

DiLuigi AJ, Engmann L, Schmidt DW et al. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertil Steril 2010;94(3):1111-1114.

Fauser B, Jong D, Olivennes F, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87:709–715.

Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, et al. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010;93:847–854.

Seyhan A, Ata B, Polat M, et al. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod. 2013;28(9):2522-2528.

Tsampras N, Palinska-Rudzka K, Alebrahim Y, et al. Prevention of ovarian hyperstimulation syndrome (OHSS): British Fertility Society policy and practice guideline. Hum Fertil (Camb) 2025;28(1):2441827.

Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014 Oct 31;2014(10):CD008046.

Beebeejaun Y, Copeland T, Duffy JMN, et al. Triggering oocyte maturation in in vitro fertilization treatment in healthy responders: a systematic review and network meta-analysis. Fertil Steril 2025;123(5):812-826.

Aflatoonian A, Mansoori-Torshizi M, Farid Mojtahedi M, et al. Fresh versus frozen embryo 5271 transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone 5272 antagonist cycles among high responder women: A randomized, multi-center study. Int J Reprod Med 2018;16: 9-18.

Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013;28:2511–2521.

Iorio GG, Carbone L, Conforti A, et al.Ovarian Hyperstimulation Syndrome after GnRH Agonist Triggering and Freeze-All Protocol? Never Not, Hardly Ever: A Systematic Review of Case Reports. Gynecol Obstet Invest 2022; 87 (5): 259–265.

Forgiarini A, Contreras MSP, Bontá S, et al. Severe ovarian hyperstimulation syndrome in an oocyte donor despite preventive strategies. Clin Exp Reprod Med 2025;52(1):101-105.

The ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, Griesinger G, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open 2020:2:1-13

Borges E Jr, Braga DP, Setti AS, et al. Strategies for the management 5279 of OHSS: Results from freezing-all cycles. JBRA assisted reproduction 2016;20: 8-12.

Chen Z, Shi Y, Sun Y,, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. New Engl J Med (2016) 375:523–533.

58. Leathersich S , Roche C, Hart R. Minimising OHSS in women with PCOS. Front Endocrinol (Lausanne) 2025 Mar 13:16:1507857.

Ata B, Humaidan P.Ovarian hyperstimulation syndrome - a complication of the past. Reprod Biomed Online 2025;50(4):104792.

Tang H, Mourad S, Zhai SD, et al. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2016;11(11):CD008605.

Shrem G, Steiner N, Balayla JUse of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome. Reprod Biomed Online 2019;39(3):433-438.

Isikoglu M, Berkkanoglu M, Senturk Z, et al. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive tech- nology program: a prospective randomized placebo-controlled double blind study. Fertil Steril 2007;88:982–985.

Venetis CA, Kolibianakis EM, Toulis KA, et al. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaa- nalysis. Fertil Steril 2011;95:188–196.

Youssef MA, Mourad S. Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2016 Aug 31;2016(8):CD001302

Kwan I, Bhattacharya S, Woolner A. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database Syst Rev 2021;4:CD005289.

Blumenfeld Z. The Ovarian Hyperstimulation Syndrome. Vitam Horm 2018;107:423-451

Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 201;4(2):70-75

Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008;90 Suppl 5:S188–193.

Carter R, Petrie K, Sadighi A, et al. Ovarian hyperstimulation syndrome on the acute medical unit: A problem-based review. Acute Medicine 2015:14, 21–27.

. Bülent Güçyetmez B, Ayyıldız AÇ. Bir Tedavi Yaklaşımının İstenmeyen Komplikasyonu: Ovaryen Hiperstimülasyon Sendromu (OHSS). Türk Yoğun Bakım Derneği Dergisi 2013:11: 47-53

Maslovitz S, Jaffa A, Eytan O,,et al. Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation. Obstet Gynecol 2004;104:321–326.

Ozgun MT, Batukan C, Oner G, et al. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome. Gynecol Endocrinol 2008;24:656–658.

Csokmay JM, Yauger B.J, Henne MB, et al.. Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “tap early and often” versus hospitalization. Fertil Steril 2010:93, 167–173.

Gebril A, Hamoda H, Mathur R. Outpatient management of severe ovarian hyperstimulation syndrome: a systematic review and a review of existing guidelines. Hum Fertil 2018;21(2):98-105.

Stouffs K, Daelemans S, Santos-Ribeiro S, et al. Rare genetic variants potentially involved in ovarian hyperstimulation syndrome. J Assist Reprod Gene 2019;36(3):491-497.

Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 2014;101: 967–973.

Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85:112–120

Sahin Y, Kontaş O, Cankurtaran M. Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit. Gynecol Endocrinol. 1997;11(4):231-236.

McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-236.

Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 2000;74:429–438

Soares SR, Gomez R, Simon C, et al. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008;14:321-333

Golan A, Weissman A. Symposium: update on prediction and management of OHSS. A modern classification of OHSS. Reprod Biomed Online. 2009;19:28–32

Practice Committee of the American Society for Reproductive MedicinePrevention of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2024;121:230-245

Royal College of Obstetricians and Gynaecologists. The management of Ovarian Hyperstimulation Syndrome: Green-Top Guideline No. 5. 3rd ed. London: RCOG 2016.

Griesinger G, Verweij PJ, Gates D, et al. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol. PloS one 2016;11: (3):1-14

Papanikolaou EG, Humaidan P, Polyzos NP, et al. Identification of the high-risk patient for ovarian hyperstimulation syndrome. Semin Reprod Med 2010, 28:458–462.

Schouten N, Wang R, Torrance H, et al. Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis. Hum Reprod Update 2025;31(2):116-132.

Nakhuda GS, Chu MC, Wang JG, et al. Elevated serum Mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril 2006;85:1541–1543.

Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antiMullerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol 2014;211(1):59.e1-8.

Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. J Fertil Steril 2012;98(3):657-663.

Sousa M, Cunha M, Teixeira da Silva J, et al. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles. Reprod Biol Endocrinol 2015;13:66. DOI 10.1186/s12958-015-0067-3

Selter J, Wen T, Palmerola KL, et al. Life– threatening complications among women with severe ovarian hyperstimulation syndrome. Am J Obstet Gynecol 2019;220(6):575.e1-575.e11.

Nenonen HA, Lindgren IA, Prahl AS, et al. The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation. Pharmacogenet Genomics 2019;29:114–120.

Tso LO, Costello MF, Albuquerque LET, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2020;12: Cd006105

Hussein RS, Elnashar I, Amin AF, et al. Effect of Metformin on Premature Luteinization and Pregnancy Outcomes in Intracytoplasmic Sperm Injection-Fresh Embryo Transfer Cycles: A Randomized Double-Blind Controlled Trial. Int J Fertil Steril 2021;15: 108-114.

Toftager M, Bogstad J, Bryndorf T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod 2016;31:1253–1264.

Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016;4:CD001750.

Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev 2017;1(1):CD012103.

Lambalk CB, Banga FR, Huirne JA, et al.. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update 2017;23:560–579.

Wang R, Lin S, Wang Y, et al. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: a systematic review and meta-analysis. PLoS ONE 2017;12:e0175985.

Kadoura S, Alhalabi M, Nattouf AH. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis. Sci Rep 2022;12:4456.

Palomba S, Costanzi F, Nelson SM, et al. Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence. Reprod Biol Endocrinol 2023;21(1):67.

Yu S, Long H, Chang HY, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod 2018;33:229–237.

Massin N. New Stimulation Regimens: Endogenous and Exogenous Progesterone Use to Block the LH Surge During Ovarian Stimulation for IVF. Hum Reprod Update 2017;23:211–220.

Ye H, Shi L, Quan X, et al. Cumulative live birth rate of in vitro fertilization cycle via progestin-primed ovarian stimulation versus gonadotropin-releasing hormone antagonist protocol in infertile women with normal ovarian reserve: an open-label, randomized controlled trial. Human fertility 2024;27, No1, 1-10. 2316005.

Guan S, Feng Y, Huang Y, et al. Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: a meta- analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2021;12:702558.

Chen ZQ, Ai A, Zhang Y, et al. A randomized controlled trial to compare the live birth rate of the first frozen embryo transfer following the progestin-primed ovarian stimulation protocol vs. the antagonist protocol in women with an anticipated high ovarian response. Fertil steril 2024;121: 937-945.

Iaconelli CAR, Setti AS, Braga DPAF, et al. Concomitant use of FSH and low-dose recombinant hCG during the late follicular phase versus conventional controlled ovarian stimulation for intracytoplasmic sperm injection cycles. Hum Fertil (Camb) 2017;20:285–292.

Lensen SF, Wilkinson J, Leijdekkers JA, et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev 2018;2:CD012693.

Oudshoorn SC, van Tilborg TC, Eijkemans MJC, et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder. Hum reprod 2017;32: 2506-2514.

Schouten N, Wang R, Torrance H, et al. Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis. Hum Reprod Update 2025;31(2):116-132.

Ngwenya O, Lensen SF, Vail A,et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database Syst Rev 2024;1: Cd012693.

Kamath MS, Maheshwari A, Bhattacharya S, et al. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation. Cochrane Database Syst Rev 2017;11:CD008528

Sohrabvand F, Sheikhhassani S, Bagheri M et al. Comparison of highly purified urinary versus recombinant FSH: Effect on ART outcomes in polycystic ovary syndrome. Iran J Reprod Med 2012;10(3):229-236.

Van Wely M, Kwan I, Burt AL, et al. HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev 2011;2011:CD005354.

Cozzolino M, Vitagliano A, Cecchino GN, et al. Corifollitropin alfa for ovarian stimulation in in vitro fertilization: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2019;111:722–733.

D'Angelo A, Brown J, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011 Jun 15;(6):CD002811.

DiLuigi AJ, Engmann L, Schmidt DW et al. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertil Steril 2010;94(3):1111-1114.

Fauser B, Jong D, Olivennes F, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87:709–715.

Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, et al. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010;93:847–854.

Seyhan A, Ata B, Polat M, et al. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod. 2013;28(9):2522-2528.

Tsampras N, Palinska-Rudzka K, Alebrahim Y, et al. Prevention of ovarian hyperstimulation syndrome (OHSS): British Fertility Society policy and practice guideline. Hum Fertil (Camb) 2025;28(1):2441827.

Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014 Oct 31;2014(10):CD008046.

Beebeejaun Y, Copeland T, Duffy JMN, et al. Triggering oocyte maturation in in vitro fertilization treatment in healthy responders: a systematic review and network meta-analysis. Fertil Steril 2025;123(5):812-826.

Aflatoonian A, Mansoori-Torshizi M, Farid Mojtahedi M, et al. Fresh versus frozen embryo 5271 transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone 5272 antagonist cycles among high responder women: A randomized, multi-center study. Int J Reprod Med 2018;16: 9-18.

Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013;28:2511–2521.

Iorio GG, Carbone L, Conforti A, et al.Ovarian Hyperstimulation Syndrome after GnRH Agonist Triggering and Freeze-All Protocol? Never Not, Hardly Ever: A Systematic Review of Case Reports. Gynecol Obstet Invest 2022; 87 (5): 259–265.

Forgiarini A, Contreras MSP, Bontá S, et al. Severe ovarian hyperstimulation syndrome in an oocyte donor despite preventive strategies. Clin Exp Reprod Med 2025;52(1):101-105.

The ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, Griesinger G, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open 2020:2:1-13

Borges E Jr, Braga DP, Setti AS, et al. Strategies for the management 5279 of OHSS: Results from freezing-all cycles. JBRA assisted reproduction 2016;20: 8-12.

Chen Z, Shi Y, Sun Y,, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. New Engl J Med (2016) 375:523–533.

58. Leathersich S , Roche C, Hart R. Minimising OHSS in women with PCOS. Front Endocrinol (Lausanne) 2025 Mar 13:16:1507857.

Ata B, Humaidan P.Ovarian hyperstimulation syndrome - a complication of the past. Reprod Biomed Online 2025;50(4):104792.

Tang H, Mourad S, Zhai SD, et al. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2016;11(11):CD008605.

Shrem G, Steiner N, Balayla JUse of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome. Reprod Biomed Online 2019;39(3):433-438.

Isikoglu M, Berkkanoglu M, Senturk Z, et al. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive tech- nology program: a prospective randomized placebo-controlled double blind study. Fertil Steril 2007;88:982–985.

Venetis CA, Kolibianakis EM, Toulis KA, et al. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaa- nalysis. Fertil Steril 2011;95:188–196.

Youssef MA, Mourad S. Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2016 Aug 31;2016(8):CD001302

Kwan I, Bhattacharya S, Woolner A. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database Syst Rev 2021;4:CD005289.

Blumenfeld Z. The Ovarian Hyperstimulation Syndrome. Vitam Horm 2018;107:423-451

Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 201;4(2):70-75

Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008;90 Suppl 5:S188–193.

Carter R, Petrie K, Sadighi A, et al. Ovarian hyperstimulation syndrome on the acute medical unit: A problem-based review. Acute Medicine 2015:14, 21–27.

. Bülent Güçyetmez B, Ayyıldız AÇ. Bir Tedavi Yaklaşımının İstenmeyen Komplikasyonu: Ovaryen Hiperstimülasyon Sendromu (OHSS). Türk Yoğun Bakım Derneği Dergisi 2013:11: 47-53

Maslovitz S, Jaffa A, Eytan O,,et al. Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation. Obstet Gynecol 2004;104:321–326.

Ozgun MT, Batukan C, Oner G, et al. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome. Gynecol Endocrinol 2008;24:656–658.

Csokmay JM, Yauger B.J, Henne MB, et al.. Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “tap early and often” versus hospitalization. Fertil Steril 2010:93, 167–173.

Gebril A, Hamoda H, Mathur R. Outpatient management of severe ovarian hyperstimulation syndrome: a systematic review and a review of existing guidelines. Hum Fertil 2018;21(2):98-105.